Adenocarcinoma, a molecular perspective.
Stahel
R A
RA
Clinic and Policlinic of Oncology, University Hospital, Zürich, Switzerland.
D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D002471:Cell Transformation, Neoplastic; D066246:ErbB Receptors; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D008967:Molecular Biology; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D012907:Smoking / Q000009:adverse effects
D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; C482119:BRAF protein, human